Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/120347541201600504 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
J Clin Oncol
May 2024
Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India.
Purpose: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription.
View Article and Find Full Text PDFLeukocytoclastic vasculitis associated with capecitabine.
J Oncol Pharm Pract
October 2024
Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey.
Background: Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).
View Article and Find Full Text PDFProton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
Anticancer Res
May 2022
Department of Pharmacy, Osaka University Hospital, Suita, Japan.
Article Synopsis
- The study investigates the role of proton pump inhibitors (PPIs) in reducing hand-foot syndrome (HFS), a common side effect of capecitabine chemotherapy in breast cancer patients.
- It analyzed data from 195 patients, revealing that those who used PPIs had a significantly lower incidence of severe HFS (18%) compared to those who did not use PPIs (43%).
- Although PPIs were effective in reducing HFS and decreasing treatment discontinuation rates, they did not show a significant impact on progression-free or overall survival in patients.
P38 MAPK, NF-κB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.
Chem Res Toxicol
March 2022
Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, Department of Clinical Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310000, People's Republic of China.
Hand-foot syndrome (HFS) is a major adverse reaction to capecitabine (CAP). The exact pathogenesis of this disease remains unclear. In this study, metabolomics combined with cell RNA sequencing was used to study the mechanisms of CAP-induced HFS.
View Article and Find Full Text PDFUse of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.
Sci Rep
April 2021
Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis. Proton pump inhibitors (PPIs) have been reported to have anti-inflammatory effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!